Media coverage about Enzo Biochem (NYSE:ENZ) has been trending somewhat positive on Monday, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Enzo Biochem earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.7755865801006 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- mTOR Inhibitors Market to Offer Lucrative Opportunities By 2020 (openpr.com)
- Authentidate : Aeon Global Health, Operating Arm of Authentidate Holding Corp., Names David C. Goldberg as its new Chief Operating Officer (4-traders.com)
- Uveitis Treatment Market to Record a Sluggish CAGR of 7.3% through 2014-2020 (mynewsdesk.com)
- Human Papillomavirus Testing Market Is Projected to Reflect at 7.6% CAGR by 2025 (sbwire.com)
- Oxidative Stress Assay Sales Market 2017 to 2022 Global Research, Analysis and Forecast (mynewsdesk.com)
A number of equities research analysts have issued reports on ENZ shares. BidaskClub lowered Enzo Biochem from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Zacks Investment Research raised Enzo Biochem from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Tuesday, June 20th.
Enzo Biochem (NYSE ENZ) traded down 2.03% on Monday, hitting $10.64. The stock had a trading volume of 236,862 shares. The firm has a market cap of $493.77 million, a PE ratio of 14.92 and a beta of 0.92. The company’s 50 day moving average is $11.10 and its 200 day moving average is $9.70. Enzo Biochem has a 12-month low of $4.88 and a 12-month high of $12.04.
WARNING: This report was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/18/enzo-biochem-enz-receives-media-sentiment-score-of-0-11.html.
Enzo Biochem Company Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.